One of the most common molecular changes in tumor cells is the heightened rate of de novo lipid synthesis compared to their normal counterparts. The aberrant lipogenesis in cancer cells is mediated by increased expression and activity of key lipogenic enzymes primarily fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACC). Interestingly, the alterations in these key lipogenic enzymes are critical for the development and maintenance of the malignant phenotype (1). It occurs at early stages of tumorigenesis and http://www.jbc.org/cgi
One of the most common molecular changes in tumor cells is the heightened rate of de novo lipid synthesis compared to their normal counterparts. The aberrant lipogenesis in cancer cells is mediated by increased expression and activity of key lipogenic enzymes primarily fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACC). Interestingly, the alterations in these key lipogenic enzymes are critical for the development and maintenance of the malignant phenotype (1) . It occurs at early stages of tumorigenesis and becomes more pronounced in advanced cancers (1, 2) . Overexpression of FAS correlates with poor prognosis in several types of human malignancies including ovarian cancer (3, 4) . Furthermore, tumor cells depend heavily on or are "addicted" to de novo lipid synthesis to meet their energetic and biosynthetic needs, irrespective of the nutritional supplies in the circulation (1) . Consistent with this, pharmaceutical inhibitors of FAS suppress tumor cell proliferation and survival, and enhance cytotoxic killing by therapeutic agents (5) (6) (7) (8) (9) (10) . However, one barrier to cancer patient applications of these inhibitors is their nonselective suppression of fatty acid synthesis in both normal and malignant tissues, which could deteriorate weight loss, anorexia, fatigue and other cancer-associated complications. To target lipid anabolism in tumors specifically, it is important to identify the mechanism for the hyperactive lipogenesis in cancer cells, which is, however, poorly understood.
Lysophosphatidic acid (LPA), the simplest phospholipid, has been long known as a mediator of oncogenesis (11) . LPA is present at high levels in ascites of ovarian cancer patients and other malignant effusions (11) (12) (13) . LPA is a ligand of at least six G protein-coupled receptors (GPCRs) (14) . The LPA 1 /Edg2, LPA 2 /Edg4 and LPA 3 /Edg7 receptors are members of the endothelial differentiation gene (Edg) family, sharing 46 -50% amino acid sequences identity (14) . GPR23/P2Y9/LPA 4 of the purinergic receptor family and the related GPR92/LPA 5 and P2Y5/LPA 6 have been identified as additional LPA receptors, which are structurally distant from the LPA 1-3 receptors (14, 15) . The Edg LPA receptors, in particular LPA 2 is overexpressed in many types of human malignancies including ovarian cancer (11, 16) . Strong evidence implicates LPA 2 in the pathogenesis of ovarian, breast and intestine tumors (16) (17) (18) , although the exact oncogenic processes involved remain elusive.
In the present study, we observed that LPA stimulated proteolytic activation of two isoforms of the sterol regulatory element binding proteins (SREBPs), transcription factors involved in regulation of FAS and other lipogenic enzymes for biosynthesis of fatty acid and cholesterol. In addition, LPA induces dephosphorylation of AMPKα at Thr-172 and concomitant dephosphorylation of ACC at Ser-79. The dephosphorylation of ACC at Ser-79 is associated with activation of the enzyme (19) . These LPAinduced changes in the lipogenic enzymes occurred hours after exposure to LPA and the effects were sustained for many hours. Consistent with LPA activating these lipogenic pathways, LPA increased de novo lipid synthesis. We identified LPA 2 , the receptor subtype overexpressed in ovarian cancer and other human malignancies, as the key receptor responsible for delivery of the lipogenic effect of LPA. The intracellular G 12/13 -Rho signaling cascade is critical for LPA activation of the SREBP while G q -PLC is involved in LPA-mediated dephosphorylation and inhibition of AMPK. These findings reveal a novel mode of the cancer cellspecific regulation of lipogenesis by an intercellular factor present in the circulation and tumor microenvironments.
3-methylglutaryl-CoA (HGM-CoA) reductase and GAPDH were obtained from Applied Biosystems (Carlsbad, CA). Calpain I inhibitor, water soluble cholesterol, the FAS inhibitor C75, the ACC inhibitor TOFA and sodium palmitate were purchased from Sigma-Aldrich (St. Louis, MO).
Cell Culture -The sources of ovarian cancer cell lines used in the study were described previously (20) . These cells were cultured in RPMI medium supplemented with 10% FBS, 100 U/ml penicillin, and 100 µg/ml streptomycin. IOSE-29 was originally obtained from Dr. N. Auersperg (University of British Columbia, Canada) and cultured as described previously (21) .
siRNA, plasmids and transfection -The siRNA oligos for LPA 1 , LPA 2 LPA 3, and FAS were obtained from Applied Biosystems. These siRNAs were transfected into cells using Dharmafect 1 following the manufacturer's protocol. In brief, cells were plated in 6-well plates to reach 50-60% confluence before transfection. Cells were then transfected with target specific siRNA or nontargeting control siRNA (150 picoM) with Dharmafect 1 (4 µL) for 12-16 hours. Approximately 48 hours post transfection, the cells were serum starved overnight before LPA treatment. Lentiviruses carrying short hairpin RNA (shRNA) for LPA 1-3 receptors were kind gifts from Dr. S. Huang (Medical College of Georgia) (22) . The expression vector pcDNA3 expressing dominant negative form of G i was provided by Dr. P. Hylemon (Virginia Commonwealth University) (23, 24) . The G q and G 12 cDNAs were provided by Dr. RD Ye (University of Illinois at Chicago). The dominantnegative mutants of G q (G208A) and G 12 (G228A) (25) (26) (27) in pcDNA3 were made using the QuikChange XL site directed mutagenesis kit (Stratagene, Santa Clara, CA). The plasmids and the vectors expressing N19Rho and Botulinum toxin C3 were described previously (28, 29) . These plasmids were transfected into ovarian cancer cell lines using Lipofectamine LTX plus (Invitrogen) following the manufacturer's instruction.
Luciferase assays -The SREBP responsive luciferase reporter vector (pGL2-3xSREBP-TKLuc) was generated by cloning 3 repeats of the SREBP consensus sequence (AAAATCACC CCACTGCAAACTCCTCCCCCTGC) (30, 31) into the NheI and HindIII sites in front of the herpes simplex virus thymidine kinase (TK) gene promoter (-35 to +50) in the pGL2-TK-Luc vector (32) . Ovarian cancer cell lines were transfected with the luciferase vector using TransIT-TKO according to the manufacturer's protocol. About 48 hours after transfection, the cells were starved overnight and treated with LPA or vehicle (BSA) for 12 hours. Cell extracts were prepared and assayed for luciferase activity using the luciferase assay kits from Promega.
Western blotting -Cells were lysed as previously described (33 Quantitative PCR (qPCR) -Total cellular RNA was isolated from cultured cells using Trizol (Invitrogen). Complementary DNA (cDNA) was synthesized using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). The relative levels of LPA 1 , LPA 2 , LPA 3 , HMGCoA reductase and GAPDH were determined by qPCR using gene specific probes, the TaqMan Universal PCR Master Mix, and the Applied Biosystems 7900HT Real-Time PCR System. Measurement of de novo lipid synthesis -Cells were grown in 6-well plates and serum starved prior to treatment with LPA or vehicle for 24 hours. The cells were labeled with 14 C acetic acid (5 μCi/ml) for the last 6 hours of incubation. The cells were then washed twice with PBS and lysed with lysis buffer (25 mM HEPES, 150 mM NaCl, 0.1% SDS, 1% Triton X-100, 0.2 mM EDTA, 0.5% sodium deoxycholate, 20 mM glycerophosphate, 1 mM sodium vanadate, 1 mM PMSF, 10 μg/ml leupeptin and 10 μg/ml aprotinin). Lipids were extracted using a chloroform:methanol solution (2:1). Phase separation was achieved by centrifugation at 3200 x g for 10 minutes. The organic phase was extracted and dried with speed vacuum. Lipids were dissolved in Ultima Gold Cocktail (Perkin Elmer, Waltham, MA) and counted using Beckman LS 6500 scintillation counter. Each measurement was performed in triplicate and normalized to cell numbers.
Lipid staining -Cells were grown and serum starved prior to treatment with LPA or vehicle for 24 hours. Cells were then stained with BODIPY 493/503 at final concentration of 0.5 μg/ml in PBS at 37°C for 30 minutes, followed by counter staining with Hoechst (10 μg/ml) for 15 minutes. Cells were then fixed with 2% paraformaldehyde and visualized with fluorescence microscopy.
Quantification of triacylglycerols (TAG) and phospholipids -TAG and phospholipids were extracted and quantified with the EnzyChrom Triglyceride Assay kit and the EnzyChrom Phospholipid Assay kit (BioAssay Systems, Hayward, CA), respectively, according to the manufacturer.
Statistics -All numerical data were presented as mean ± SD. The statistical significances of differences were analyzed using Student's t test where p<0.05 was considered statistically significant. In all figures, the statistical significances were indicated with * if p < 0.05 or ** if p < 0.01.
RESULTS
LPA induces proteolytic cleavage and activation of SREBP in a cholesterol-sensitive manner -The hyperactive lipogenesis is a hallmark of tumor cells (1, 34) . To identify pathophysiological mechanisms driving the lipogenic program in cancer cells, we examined the potential role of LPA, an endogenous regulator of many cellular functions in ovarian cancer and other human malignancies. We first assessed whether LPA was capable of activating the SREBP transcription factors that play crucial roles in regulating expression of lipogenic enzymes. Treatment of Caov-3, OVCA-432 and other ovarian cancer cell lines including OVCAR-3 with LPA induced cleavage of the precursor forms of SREBP-1 and SREBP-2 in a time-dependent manner (Fig. 1A) . The cleaved, mature forms of SREBP-1 and SREBP-2 were detectable at 4 hours and peaked at 12 hours post LPA treatment. In contrast to the ovarian cancer cell lines, LPA failed to activate SREBP-1 or SREBP-2 in the immortalized ovarian surface epithelial cell line IOSE-29 (Fig. 1A) or normal ovarian epithelial cells (data not shown), suggesting a cancer cellspecific mechanism for SREBP activation by LPA in ovarian cancer cells.
In physiological conditions, SREBP-1 and SREBP-2 are regulated by the intracellular sterol content. In their precursor forms, SREBPs are attached to the endoplasmic reticulum (ER). Specific signaling cues such as reduced cholesterol levels trigger SREBP cleavage-activating protein (SCAP)-mediated transport of SREBP from ER to Golgi, where they are cleaved by proteases S1P and S2P to release the mature/active form (35) . At high sterol concentrations, the SREBP/SCAP complex is retained in the ER due to increased binding to INSIG proteins (36) . To determine whether LPA activation of SREBP could bypass cholesterol regulation, we preloaded Caov-3 and OVCA-432 cells with cholesterol (10 μg/ml) complexed with 0.1% fraction V fatty acid-free BSA in PBS, and then assessed activation of SREBP-1 in response to LPA. As shown in Fig.  1B , cholesterol treatment reduced both basal and LPA-induced active SREBP-1 levels, indicating that activation of SREBP by LPA remains sensitive to the cholesterol availability.
To determine whether LPA-induced SREBP cleavage is sufficient to activate SREBP transcriptional activity, Caov-3 and OVCA-432 cells were transfected with the SREBP responsive reporter pGL2-3xSREBP-TK-Luc. As shown in Fig. 1C , treatment of transfected cells with LPA significantly enhanced luciferase activity in these cells. Similar to the SREBP cleavage, SREBPdependent luciferase activity was also sensitive to cholesterol treatment (Fig. 1C) .
LPA induces expression of the SREBP target genes FAS, ACC and HMG-CoA reductase -
To substantiate the biological significance of SREBP activation by LPA, we monitored expression levels of FAS, ACC, and HMG-CoA reductase. These are well known targets of SREBP-1 and SREBP-2 involved in biosynthesis of fatty acid and cholesterol. Treatment of Caov-3, OVCA-432 and OVCAR-3 cells with LPA increased expression levels of FAS and ACC proteins as shown in Fig. 2A . The mRNA levels of these key enzymes for fatty acid synthesis (data not shown) and the rate-limiting enzyme for cholesterol synthesis HMG-CoA reductase were also significantly increased by treatment of ovarian cancer cell lines with LPA (Fig. 2B) , providing evidence that activation of SREBP-1 and SREBP-2 by LPA is sufficient to increase expression of key endogenous lipogenic enzymes in ovarian cancer cells.
LPA induces dephosphorylation of AMPK and ACC -In addition to transcriptional upregulation, the activity of ACC is inhibited by AMPK mediated phosphorylation. AMPK, a highly conserved protein serine/threonine kinase, acts as energy sensor and regulator of cellular metabolism, shutting down energy-consuming anabolic processes and activating energy-yielding catabolic processes (37) . AMPK is activated through phosphorylation of Thr-172 within the activation domain of α-subunit (38) . To determine the effect of LPA on AMPK and its downstream target ACC, we analyzed the phosphorylation status of AMPKα at this residue as a surrogate of activation of the enzyme. Treatment of Caov-3 and OVCA-432 cells with LPA induced late onset and sustained dephosphorylation of AMPKα (Fig. 3) . The decrease in AMPKα phosphorylation was detectable at 8 hours and became prominent at 12 hours. Consistent with a predominant role of AMPKα in phosphorylation of ACC, AMPKα dephosphorylation in LPA-treated cells was accompanied by a decrease in ACC phosphorylation at Ser-79 (Fig.  3) . Dephosphorylation of this site is known to enhance ACC enzymatic activity. The effects of LPA on dephosphorylation of AMPKα and ACC were not detected in IOSE-29 cells (data not shown). These results establish that LPA signaling is coupled to activation of ACC via inhibition of AMPK.
LPA promotes de novo lipid synthesis -Few studies have examined the role of exogenous factors in regulation of lipogenesis in cancer cells (5, 39) . We examined whether LPA-induced activation of lipogenic enzymes is functionally sufficient to stimulate de novo lipid synthesis. The ovarian cancer cell lines Caov-3 and OVCA-432, and the immortalized IOSE-29 cells were treated with LPA or BSA as vehicle control and pulse labeled with 14 C acetic acid to monitor the amount of new lipid synthesis. As demonstrated in Fig. 4A (left), LPA treatment led to a significant increase in 14 C incorporation into the cellular lipid fractions, reflecting an increase in newly synthesized lipids in response to LPA. The lipogenic effect of LPA was specifically detected in multiple ovarian cancer cell lines but not in the non-transformed IOSE-29 cells wherein LPA failed to induce SREBP activation or AMPK dephosphorylation. Since these cells were treated with LPA in serum-free medium lacking extracellular fatty acids, we wanted to determine if the increase in lipogenesis in response to LPA is influenced by availability of extracellular lipids. As shown in Fig. 4A (right) , exogenously supplemented palmitate slightly reduced LPAdriven lipogenesis. The reduction was, however, statistically insignificant, indicating that the lipogenic role of LPA is largely independent of availability of extracellular fatty acids. Consistent with the pro-lipogenic action of LPA, staining with a lipophilic dye BODIPY 493/503 revealed that LPA induced moderate increases in the intracellular contents of neutral lipids in Caov-3 and OVCA-432 cells but not in IOSE-29 cells (Fig. 4B) . These results were further supported by the increases in both cellular TAG and phospholipids following LPA treatment (Fig. 4C  & 4D) . LPA 2 is the major receptor subtype responsible for regulation of SREBP and AMPK -Caov-3, OVCA-432 and other ovarian cancer cell lines express the Edg LPA receptors LPA 1 , LPA 2 , and LPA 3 (Fig. 5A) . The other non-Edg LPA receptors are either absent or expressed inconsistently in ovarian cancer cells (40, 41) . Thus, we focused on the potential role of LPA [1] [2] [3] in the regulation of lipogenesis. We used siRNA to knockdown expression of LPA 1 , LPA 2 , and LPA 3 in Caov-3 cells and examined SREBP activation and AMPKα dephosphorylation in response to LPA treatment. Interestingly, only knockdown of LPA 2 remarkably attenuated LPA-induced cleavage of SREBP-1, dephosphorylation of AMPKα at Thr-172 (Fig. 5B) as well as expression of FAS and ACC (Fig. 5C ). There were little inhibitory effects on SREBP-1 activation, AMPKα dephosphorylation and expression of FAS and ACC in conjunction with LPA 1 or LPA 3 knockdown. We encountered a technical difficulty in achieving efficient knockdown of LPA receptors with transient siRNA in OVCA-432 cells. However, similar results were obtained from OVCA-432 cells when LPA receptors were stably knocked down by lentivirus-transduced shRNA (Fig. 5B & 5C) . These results support a primary role of the LPA 2 receptor in LPA-dependent activation of SREBP-1 and inhibition of AMPKα. However, overexpression of LPA 2 in IOSE-29 cells was not sufficient to activate LPA-dependent induction of FAS and ACC (data not shown), suggesting that additional signaling player(s) present specifically in malignant cells is involved.
To verify this receptor subtype-specific regulation of lipogenesis, we examined the effect of LPA 2 knockdown on LPA-driven lipogenesis. The de novo lipid synthesis in LPA receptor knockdown and control cells was assessed as described earlier.
The endogenous lipid synthesis induced by LPA was strongly attenuated by siRNA or shRNA mediated downregulation of LPA 2 (Fig 5D) . In contrast, knockdown of LPA 3 (Fig. 5D) (42) . We transfected dominant negative forms of these G proteins into highly transfectable Caov-3 cells in an effort to screen for G proteins critical for LPA-dependent SREBP-1 cleavage and AMPKα dephosphorylation. As shown in Fig. 6A , expression of the dominant negative G 12 attenuated LPA-induced SREBP-1 cleavage but not LPA-induced dephosphorylation of AMPKα. In contrast, expression of dominant negative G q inhibited AMPKα dephosphorylation but not SREBP-1 cleavage induced by LPA. Thus, different G protein cascades are implicated in the regulation of SREBP and AMPK by LPA. Since a prominent effector of G 12/13 is the Rho GTPase, we examined whether Rho is required for LPA activation of SREBP. As expected, expression of dominant negative Rho (N19Rho) or Botulinum toxin C3, a specific inhibitor of Rho GTPase, suppressed LPA-induced cleavage of SREBP-1 (Fig. 6B ) as compared to vector-transfected cells. The results demonstrate that LPA 2 promotes SREBP activation in a Rho-dependent pathway.
To elucidate the regulatory network leading to AMPK dephosphorylation, we used pharmacological inhibitors of signaling molecules downstream of G q . As shown in Fig. 6C , the PLC inhibitor U73122 but not it's inactive analog U73433 blocked AMPKα dephosphorylation induced by LPA. The data supports a G q -PLCdependent mechanism to control phosphorylation and activity of AMPKα in LPA-treated cells.
LPA-driven cell proliferation requires LPA 2 and de novo lipid synthesis -LPA is a mitogen that stimulates proliferation of ovarian cancer cells (43) (44) (45) (46) . To understand biological significance of LPA-induced lipogenesis, we examined whether the pro-lipogenic activity of LPA contributes to LPA-driven proliferation of ovarian cancer cells. C75 and TOFA are well characterized, specific inhibitors of FAS and ACC, respectively (47, 48) . The presence of C75 dramatically decreased cell numbers of Caov-3 and OVCA-432 cells in serum-free medium supplemented with LPA as a growth factor (Fig. 7A) , suggesting that the blockade of de novo lipogenesis could attenuate LPA-induced cell proliferation. Similar effects were observed in the presence of the ACC inhibitor TOFA (data not shown). At the concentrations we used, C75 and TOFA did not induce significant increases in apoptosis or appreciable decreases in cell viability (data not shown), suggesting that these inhibitors mainly targeted cell proliferation rather than cell survival. We also tested if exogenously added palmitate could reverse the effect of C75 on LPA-induced cell proliferation. At 10 μM, palmitate partially prevented the effect of C75 (Fig. 7B) . This ability of palmitate, however, was not seen at 20 μM, suggesting possible cytotoxic effect of high concentrations of palmitate.
To obtain molecular evidence for involvement of FAS in LPA-induced cell proliferation, we used siRNA to knockdown FAS expression in Caov-3 and OVCA-432 cells. Downregulation of FAS expression indeed prevented proliferation of these cells induced by LPA (Fig. 7C) . Finally, since LPA 2 is the key receptor subtype required for LPA activation of lipogenesis, we knocked down its expression to determine whether LPA 2 is an integral component of LPA-induced cell proliferation. As shown in Fig. 7D , following downregulation of LPA 2 , both cell lines exhibited significant decrease in growth rate when the cells were incubated in serum-free medium containing LPA. Thus LPA 2 and its associated lipogenesispromoting activity are critical for LPA-induced cell proliferation.
DISCUSSION
The majority of the adult tissues depend on dietary fat to meet their nutritional needs. In contrast, cancer cells depend on de novo lipid synthesis for generation of fatty acids, irrespective of the available extracellular supplies. Malignant cells typically show a high rate of de novo fatty acid synthesis (49, 50) . Intracellular fatty acids in rapidly dividing cancer cells not only supply energy through beta oxidation but more importantly, serve as precursors for biosynthesis of membrane phospholipids, signaling lipids and secondary messengers (51) . The lipogenic phenotype of cancer cells has been primarily attributed to increased expression or aberrant activity of the major lipogenic enzymes FAS and ACC. In particular, FAS, originally recognized as a tumor specific antigen present in serum of cancer patients (34) , is overexpressed in a variety of human malignancies. However, the cellular mechanisms by which lipogenic enzymes are upregulated in cancer cells remain poorly understood except for a few studies suggesting that steroid hormones and Her family ligands could increase FAS expression via the PI3K or MAPK pathways (52) (53) (54) (55) .
In the present study, we describe a novel LPAmediated mechanism activating de novo lipogenesis in ovarian cancer cells. We demonstrated that treatment of ovarian cancer cell lines with LPA activates the SREBP-FAS and AMPK-ACC lipogenic cascades, culminating in increased de novo lipid synthesis. The lipogenic effect of LPA was specifically observed in cancer cells as LPA failed to induce de novo lipogenesis in non-transformed IOSE-29 cells. LPA has been long known as a mediator of ovarian cancer. It is present at high concentrations in tumor microenvironments such as ascites of ovarian cancer patients and other malignant effusions (12, 13) . The present study highlights the possibility that LPA is an etiological factor in tumor microenvironments to promote lipogenesis in ovarian cancer cells although the effect of LPA in other cancer cells remains to be determined.
A significant finding of the present work is the selective role of the LPA 2 receptor in LPA activation of the lipogenic pathways and LPAdriven lipogenesis. We and others have previously shown that LPA 2 and LPA 3 are overexpressed in significant fractions of ovarian cancer and in most ovarian cancer cell lines (16, 46) . LPA 1 , which is expressed by both normal and malignant ovarian epithelial cells, is dispensable for the pro-lipogenic activity of LPA in ovarian cancer cells. It is somewhat surprising that in both Caov-3 and OVCA-432 cells, knockdown of LPA 3 slightly potentiated the lipogenic effect of LPA (Fig. 5D) . The results imply that the crosstalk among coexpressed LPA receptors is important in the control of biological outcomes of LPA. The specific role of LPA 2 in the promotion of lipogenesis in tumor cells is consistent with the increased expression of this receptor in various malignancies (16, (56) (57) (58) . Although LPA 1 and LPA 3 have also been reported to be up or downregulated in some cancers, overexpression of LPA 2 is most commonly seen in almost all cancer types examined (16, (56) (57) (58) . There is also strong evidence from xenograft mouse models and transgenic mice that LPA 2 is more oncogenic compared to LPA 1 and LPA 3 (17, 59) . The compelling evidence for the implication of LPA 2 as an oncogene stems from recent studies by Yun's group who showed the LPA 2 -deficient mice were more resistant to intestinal tumorigenesis induced by colitis or by ApcMin mutation (18, 60) . However, the molecular mechanisms for the oncogenic activity of LPA 2 are not well understood. Most previous studies have been focused on the ability of LPA 2 to stimulate expression of oncogenic protein factors including IL-6, VEGF, HIF1α, c-Myc, cyclin D1, kruppellike factor 5, and Cox-2 (18, 32, (60) (61) (62) (63) . LPA 2 seems to be more potent than other LPA receptors in driving the transcriptional effects of LPA on these LPA target genes. The current study links LPA 2 to the lipogenic phenotype of ovarian tumor cells. The role of LPA 2 in lipid metabolism provides a new avenue to explore the oncogenic role of LPA.
Different G proteins downstream of LPA 2 receptor are involved in regulation of the SREBP-FAS and AMPK-ACC pathways in LPA-treated cells. Our results showed that SREBP cleavage/activation lies downstream of the G 12/13 -Rho pathway while AMPK dephosphorylation/inhibition is mediated by the G q -PLC cascade. LPA stimulated cleavage of the precursor SREBP into mature and active forms in a time-dependent manner, which was accompanied by increases in SREBP-dependent transcriptional activity and upregulation of endogenous SREBP target genes. In addition, the effect of LPA on SREBP cleavage and activation remains sensitive to cholesterol-mediated regulation, indicating the sterol sensing machinery involved in SREBP cleavage is not disrupted by LPA. The proteolytic cleavage of SREBP is controlled by the combined action of SCAP and INSIG proteins (64) . An increase in SCAP or decrease in INSIG proteins could lead to activation of SREBP. Since androgens and insulin have been shown to regulate expression or stability of SCAP or INSIG (65, 66) , it will be of interest to determine whether LPA modulates these proteins or their ratios to activate SREBP. This possibility is consistent with the observation that SREBP cleavage occurs hours after exposure of ovarian cancer cells to LPA.
It is yet to be determined how the G q -PLC pathway is linked to dephosphorylation and inhibition of AMPKα. Obviously, our observation does not agree with Kim et al. who recently reported that LPA stimulated transient phosphorylation of AMPKα at Thr-172 within the first 10 minutes of LPA treatment in the SKOV-3 ovarian cancer cell line (67) . In our experiments involving multiple ovarian cancer cell lines, there was little change in AMPKα phosphorylation status at the early time points. Instead, we observed a time-dependent decrease in phospho-AMPKα levels, which maximized after 12 hours of incubation with LPA. The serine-threonine kinase LKB1, encoded by the Peutz-Jeghers syndrome tumor suppressor gene, is believed to be primary AMPK kinase as suggested by LKB1 knockout studies (68) (69) (70) . LKB1 possesses a nuclear localization domain and is located predominantly in the nucleus. Upon phosphorylation, LKB1 translocates to the cytoplasm where it forms an active complex with Ste20-related adaptor (STRAD) and mouse protein 25 (MO25) (71) . LPA may downregulate LKB1 activity via modulation of its phosphorylation, nuclear-cytoplasmic translocation or association with STRAD-MO25 in the cytosol. In addition, AMPK phosphorylation could be downregulated by inhibition of other candidate AMPK kinases such as calmodulin-dependent protein kinase kinase-beta (CAMKKβ) (71) or by activation of unknown AMPK phosphatase(s). A potential decrease in AMP/ATP ratio could also change the conformation of AMPK to prevent the active site (Thr-172) on the α-subunit from being exposed and phosphorylated by AMPK kinases. 
